Survival of leukemic B cells promoted by engagement of the antigen receptor
Open Access
- 15 November 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 98 (10), 3050-3057
- https://doi.org/10.1182/blood.v98.10.3050
Abstract
Hematopoietic stem cells (HSCs) represent an important target for the treatment of various blood disorders. As the source of critical cells within the immune system, genetic modification of HSCs can also be used to modulate immune responses. The effectiveness of HSC-mediated gene therapy largely depends on efficient gene delivery into long-term repopulating progenitors and targeted transgene expression in an appropriate progeny of the transduced pluripotent HSCs. Self-inactivating (SIN) lentiviral vectors have been demonstrated to be capable of transducing mitotically inactive cells, including HSCs, and accommodating a nonviral promoter to control the transgene expression in transduced cells. In this study, we constructed 2 SIN lentiviral vectors, EF.GFP and DR.GFP, to express the green fluorescent protein (GFP) gene controlled solely by the promoter of either a housekeeping gene EF-1α or the human HLA-DRα gene, which is selectively expressed in antigen-presenting cells (APCs). We demonstrated that both vectors efficiently transduced human pluripotent CD34+cells capable of engrafting nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. When the EF.GFP vector was used, constitutive high-level GFP expression was obtained in all the human HSC progeny detectable in NOD/SCID mice and in subsequent in vitro differentiation assays, indicating that engrafting human HSCs have been transduced. In contrast, the DR.GFP vector mediated transgene expression specifically in human HLA-DR+ cells and highly in differentiated dendritic cells (DCs), which are critical in regulating immunity. Furthermore, human DCs derived from transduced and engrafted human cells potently stimulated allogeneic T-cell proliferation. This study demonstrated successful targeting of transgene expression to APCs/DCs after stable gene transduction of pluripotent HSCs.Keywords
This publication has 43 references indexed in Scilit:
- CD40 Ligand in CLL Pathogenesis and TherapyLeukemia & Lymphoma, 2000
- Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.Journal of Clinical Investigation, 1998
- Role of the CD40 and CD95 (APO‐1/Fas) antigens in the apoptosis of human B‐cell malignanciesBritish Journal of Haematology, 1997
- Signals and susceptibility to programmed death in B cellsCurrent Opinion in Immunology, 1996
- Protection against Fas-dependent Thl-mediated apoptosis by antigen receptor engagement in B cellsNature, 1995
- The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoireImmunology Today, 1994
- Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.The Journal of Experimental Medicine, 1992
- Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders.The Journal of Experimental Medicine, 1990
- Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia.The Journal of Experimental Medicine, 1989
- TUMOUR NECROSIS FACTOR AS AN AUTOCRINE TUMOUR GROWTH FACTOR FOR CHRONIC B-CELL MALIGNANCIESThe Lancet, 1988